NCT02847091已完成4 期
Post-marketing Clinical Study of Ipragliflozin; Multicenter, Open-label Study to Assess the Efficacy of Ipragliflozin Add-on in Reducing Insulin Dose in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 103
- 试验地点
- 15
- 主要终点
- Change from baseline in insulin dose
研究概览
简要总结
The objective of this study is to assess the reduction in insulin dose from baseline at Week 24 while keeping the blood glucose levels controlled (maintaining HbA1c values) when ipragliflozin is administered once daily for 24 weeks in patients with type 2 diabetes mellitus receiving insulin therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject has been receiving insulin therapy for the treatment of diabetes mellitus.
- •The subject has type 2 diabetes mellitus and has been receiving insulin monotherapy or insulin therapy in combination with one or two oral hypoglycemic agents.
- •The subject has not modified diet or exercise therapies or dosage regimen of oral hypoglycemic agents, or has not switched to another pharmacotherapy for 12 weeks before Visit
- •The subject has an HbA1c value between 6.5% and <8.0%.
- •The subject has a body mass index (BMI) of >23.0 kg/m
- •If the subject is a female, she must satisfy the following criteria. The subject is not of childbearing potential and satisfies any of the following criteria.
- •The subject is post-menopausal (absence of menses for at least 1 year).
- •The subject is surgically sterile.
- •The subject is of childbearing potential but satisfies all of the following criteria:
- •The subject agrees not to get pregnant to 28 days after the last dose of the study drug.
- •The subject has a negative pregnancy test. The subject agrees to use two of the established contraceptive methods listed below to 28 days after the last dose of the study drug when having heterosexual intercourse.
- •If the subject is a female, she must agree not to breastfeed to 28 days after the last dose of the study drug.
- •If the subject is a female, she must agree not to donate their eggs during the period from the assessment to 28 days after the last dose of the study drug.
- •In case a male subject's spouse or partner is of childbearing potential, the subject must agree to use two of the established contraceptive methods to 28 days after the last dose of the study drug.
- •If the subject is a male, he must agree not to donate their sperm to 28 days after the last dose of the study drug.
排除标准
- •The subject has type 1 diabetes mellitus.
- •The subject has any symptom of dysuria, anuria, oliguria or urinary retention.
- •The subject has proliferative retinopathy.
- •The subject has diabetic ketoacidosis.
- •The subject has a history or complication of medically significant renal disease such as renovascular occlusive disease, nephrectomy and/or renal transplant.
- •The subject has a history of recurrent urinary tract infection.
- •The subject has symptomatic urinary tract infection or symptomatic genital infection.
- •The subject has chronic disease(s) that require the continuous use of corticosteroids, immunosuppressants, etc.
- •The subject has a history of cerebral vascular attack, unstable angina, myocardial infarction, vascular intervention, and serious heart disease within 1 year (52 weeks) before signing of the informed consent.
- •The subject has a complication or surgical history of serious gastrointestinal disorder.
- •The subject has severe hepatic dysfunction.
- •The subject has uncontrolled blood pressure.
- •The subject has unstable psychiatric disorder.
- •The subject has severe infection or serious trauma, or perioperative.
- •The subject has drug addiction or alcohol abuse.
- •The subject has a history of malignant tumors.
- •The subject has a history of an allergy to ipragliflozin and/or similar drugs (drugs possessing SGLT2 inhibitory action).
- •The subject has used SGLT2 inhibitors, GLP-1 receptor agonists, sulfonylureas (SU), glinide agents, or insulin products other than long-acting insulin within 12 weeks before signing of the informed consent.
研究组 & 干预措施
Ipragliflozin Group
Experimental
Ipragliflozin will be administered orally for 24 weeks.
干预措施: Ipragliflozin (Drug)
Ipragliflozin Group
Experimental
Ipragliflozin will be administered orally for 24 weeks.
干预措施: Insulin (Drug)
结局指标
主要结局
Change from baseline in insulin dose
时间窗: Baseline and Week 24
Percent change from baseline in insulin dose
时间窗: Baseline and Week 24
次要结局
- Change from baseline in insulin dose(Baseline and Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 and the last assessment during the treatment period (up to Week 24))
- Change from baseline in C-peptide(Baseline and Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and the last assessment during the treatment period (up to Week 24))
- Change from baseline in blood pressure(Baseline and Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and the last assessment during the treatment period (up to Week 24))
- Safety assessed by Hematology(Up to Week 24)
- Percent change from baseline in insulin dose(Baseline and Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 and the last assessment during the treatment period (up to Week 24))
- Change from baseline in fasting plasma glucose(Baseline and Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and the last assessment during the treatment period (up to Week 24))
- Change from baseline in cholesterol(Baseline and Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and the last assessment during the treatment period (up to Week 24))
- Change from baseline in glycoalbumin(Baseline and Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and the last assessment during the treatment period (up to Week 24))
- Change from baseline in HbA1c(Baseline and Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and the last assessment during the treatment period (up to Week 24))
- Percent of subjects achieving withdrawal of insulin therapy(Up to Week 24)
- Safety assessed by biochemistry(Up to Week 24)
- Change from baseline in leptin(Baseline and Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and the last assessment during the treatment period (up to Week 24))
- Change from baseline in glucagon(Baseline and Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and the last assessment during the treatment period (up to Week 24))
- Change from baseline in body weight(Baseline and Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and the last assessment during the treatment period (up to Week 24))
- Change from baseline in waist circumference(Baseline and Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and the last assessment during the treatment period (up to Week 24))
- Change from baseline in DTSQ(Baseline and Week 24 and the last assessment during the treatment period (up to Week 24))
- Safety assessed by incidence of Adverse events(Up to Week 24)
- Safety assessed by pulse rate in a sitting position(Up to Week 24)
- Change from baseline in adiponectin(Baseline and Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and the last assessment during the treatment period (up to Week 24))
- Number of subjects achieving withdrawal of insulin therapy(Up to Week 24)
- Safety assessed by blood pressure in a sitting position(Up to Week 24)
研究者
研究点 (15)
Loading locations...
相似试验
已完成
4 期
A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT02175784Astellas Pharma Inc262
已完成
4 期
Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)Type 2 Diabetes MellitusNCT02291874Astellas Pharma Inc100
已完成
3 期
Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on InsulinType 2 DiabetesNCT00673231AstraZeneca1,240
已完成
2 期
Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 DiabetesType 2 Diabetes MellitusNCT00831779AstraZeneca116
已完成
3 期
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor BlockerType 2 DiabetesNCT01137474AstraZeneca2,996